PCM
WGS icon

Prelude Capital Management’s GeneDx Holdings WGS Stock Holding History

Prelude Capital Management’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,591
Closed -$67.7K – 1377
2023
Q3 		$67.7K Sell
18,591
-800
-4% -$4.38K ﹤0.01% 1023
2023
Q2 		$116K Buy
+19,391
New +$153K 0.01% 915

Other funds holding WGS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prelude Capital Management's WGS Position: Q4 2023 in Review

Prelude Capital Management sold out of GeneDx Holdings (WGS) in Q4 2023, closing a stake of 18,591 shares — an estimated $67.7K sold.

Prelude Capital Management first reported a position in WGS in Q2 2023 and held it in 2 quarters. The position peaked at $116K in Q2 2023. 48 funds tracked by Wall St. Rank hold WGS as of Q4 2023.

  • Prelude Capital Management reported no remaining GeneDx Holdings position as of Q4 2023 after selling out during the quarter.
  • Prelude Capital Management sold 18,591 GeneDx Holdings shares in Q4 2023, an estimated $67.7K.
  • Prelude Capital Management first reported a position in GeneDx Holdings in Q2 2023 and held it in 2 quarters.
  • Prelude Capital Management's GeneDx Holdings position peaked at $116K in Q2 2023.
  • 48 funds tracked by Wall St. Rank held GeneDx Holdings as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.